Literature DB >> 11793625

Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.

G Csako1, N J McGriff, P Rotman-Pikielny, N J Sarlis, F Pucino.   

Abstract

OBJECTIVE: To describe a patient with primary hypothyroidism in whom ingestion of levothyroxine with calcium carbonate led to markedly elevated serum thyrotropin concentrations. CASE
SUMMARY: A 61-year-old white woman with primary hypothyroidism, systemic lupus erythematosus, celiac disease, and history of Whipple resection for pancreatic cancer was euthyroid with levothyroxine 175-188 micrograms/d. After taking a high dose of calcium carbonate (1250 mg three times daily) with levothyroxine, she developed biochemical evidence of hypothyroidism (thyrotropin up to 41.4 mU/L) while remaining clinically euthyroid. Delaying calcium carbonate administration by four hours returned her serum thyrotropin to a borderline high concentration (5.7 mU/L) within a month. Serum concentrations of unbound and total thyroxine and triiodothyronine tended to decrease, but remained borderline low to normal while the patient concomitantly received levothyroxine and calcium carbonate. DISCUSSION: Concomitant administration of levothyroxine and calcium carbonate often results in levothyroxine malabsorption. While in most patients the clinical consequences of this interaction, even with prolonged exposure, are relatively small, overt hypothyrodism may develop in patients with preexisting malabsorption disorders. However, as the current case illustrates, the clinical manifestations of the initial levothyroxine deficit may not always be apparent and, of all usual laboratory thyroid function tests, only thyrotropin measurement will reliably uncover the exaggerated levothyroxine malabsorption.
CONCLUSIONS: Decreased absorption of levothyroxine when given with calcium carbonate may be particularly pronounced in patients with preexisting malabsorption disorders. Once recognized, a change in drug administration schedule usually minimizes or eliminates this interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11793625     DOI: 10.1345/aph.1A031

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Occurrence of overt celiac disease in the elderly following total thyroidectomy.

Authors:  M Caputo; R Brizzolara; M Schiavo; C Salmaso; G Pesce; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

3.  Timing of levothyroxine administration affects serum thyrotropin concentration.

Authors:  Thien-Giang Bach-Huynh; Bindu Nayak; Jennifer Loh; Steven Soldin; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958

Review 4.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

5.  Pituitary hyperplasia: a complication of the pseudomalabsorption of thyroxine.

Authors:  Mary-Anne Doyle; Heather A Lochnan
Journal:  Int J Gen Med       Date:  2013-04-29

Review 6.  Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature.

Authors:  Emanuela Cataldo; Valeria Columbano; Louise Nielsen; Lurlynis Gendrot; Bianca Covella; Giorgina Barbara Piccoli
Journal:  BMC Nephrol       Date:  2018-07-02       Impact factor: 2.388

Review 7.  Levothyroxine Interactions with Food and Dietary Supplements-A Systematic Review.

Authors:  Agnieszka Wiesner; Danuta Gajewska; Paweł Paśko
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.